Skip to content

A Random Double-Blinded Placebo-Controlled Trial on optimization of gut microbiotal microecology and treatment of coronary heart diasease by using Bidobacterium lactis M8

A Random Double-Blinded Placebo-Controlled Trial on optimization of gut microbiotal microecology and treatment of coronary heart diasease by using Bidobacterium lactis M8

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017218
Enrollment
Unknown
Registered
2018-07-18
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

1:Bidobacterium Lactics M8
2:Placebo

Sponsors

Weihai Municipal Hospital, Shandong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patient with coronary heart disease (version 2016 diagnostic criteria); 2. Aged between 35 and 75 years; 3. Good compliance for per protocol; 4. Agree to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast-feeding women; 2. Female patients of childbearing without any contraceptive measures; 3. Those who is known or suspected to allergy on the probiotics; 4. History of gastrointestinal disorder or surgery; 5. Use of antibiotics and immunosuppressant agents in the proceeding 4 weeks or the processing; 6. Ingestion of other probiotics or other probiotis; 7. Unstable life sign and unstable pantients. 8. Acute ST segment elevate myocardial infarction ,with serious arrhythmia or shock; 9. Patients with irregular eating habits and large changes of eating habits in following-up period; 10. The patients received other clinical trials at the same time; 11. Relay on controlled drugs and alcohol; 12. Refuse to sign informed consent; 13. Patients with insufficiency of liver and kidney; 14. Patients can not persist to the terminal point of the study.

Design outcomes

Primary

MeasureTime frame
DNA of gut microbiome;Ttimethylamine N-oxide;

Secondary

MeasureTime frame
Lnterkeukin-6;martix metalloprotease-9;short chain fat acid;

Countries

China

Contacts

Public ContactXinfu Zhou

Weihai Municipal Hospital, Shandong

zxfskp@sina.com+86 18660377167

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026